Adma Biologics Inc Expected To Post A Loss Of 8 Cents A Share: Earnings Preview

ADMA Biologics

08/11/2022 03:04

* ADMA Biologics Inc  ADMA.OQ   ADMA.O  is expected to show
a rise
in quarterly revenue when it reports  results on November 9. 
    * The Ramsey New Jersey-based  company is expected to report
 a
66.7% increase in revenue to $34.484 million from $20.68 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ADMA Biologics Inc
is for
a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADMA
Biologics
Inc is $5​, above​ its last closing price of $2.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.08       -0.08      -0.07     Beat    12.5
 Mar. 31 2022  -0.08       -0.08      -0.10     Missed  -17.6
 Dec. 31 2021              -0.09      -0.09     Met     3.6​
 Sep. 30 2021  -0.14       -0.14      -0.13     Beat    9.7
 ​​Jun.        -0.13       -0.15      -0.14     Beat    6.7
 30 2021                                                
 Mar. 31 2021  -0.16       -0.17      -0.16     Beat    3.6​
 Dec. 31 2020  -0.17       -0.16      -0.20     Missed  -24.1
 Sep. 30 2020  -0.18       -0.19      -0.19     Met     -1.8
 This summary was machine generated November 8 at 03:04 GMT.  All
figures in US dollars  unless otherwise stated